| Name | Title | Contact Details |
|---|
Family Service League is a nationally accredited human services agency that has taken an active role in strengthening families and empowering the residents of Long Island for more than 90 years. We currently have over 50 programs in 21 locations, including 5 Family Centers, designed to help children, families in crisis, senior citizens, people who are homeless, unemployed, or mentally ill. Family Service League works to give them the resources they need in order to be self-reliant and productive members of our communities.
MDSave is an online marketplace for customers to shop and compare medical services the same way they shop for everything else. Patients can select their provider based on quality and clear pricing.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Serving markets in the US and Canada, Vision Group Holdings oversees and manages the leading LASIK and laser eye surgery providers in North America.
Calox is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.